Irbesartan in Marfan syndrome (AIMS): A double-blind, placebo-controlled randomised trial

The Lancet Dec 19, 2019

Mullen M, Jin XY, Child A, et al. - Researchers examined how irbesartan affects the rate of aortic dilatation in children and adults with Marfan syndrome. In this placebo-controlled, double-blind randomized trial performed at 22 centers in the UK, 192 individuals (aged 6–40 years) with clinically confirmed Marfan syndrome were recruited and were randomly allocated to receive irbesartan (n = 104) or placebo (n = 88). The irbesartan group vs the placebo group had the mean rate of aortic root dilatation of 0·53 mm per year (95% CI 0·39 to 0·67) vs 0·74 mm per year (0·60 to 0·89), respectively. Further, irbesartan led to a reduced rate of change in aortic Z score. This suggests the association of irbesartan use with a decrease in the rate of aortic dilatation in children and young adults with Marfan syndrome and with a decrease in the incidence of aortic complications.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
  • 55 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Unlimited access to original articles by experts
  • Nonloggedinlock icon
    Secure: we never sell your data
  • Signing up takes less than 2 mins
Try M3 India / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen